In 2024, IntraBio reached unicorn status with a $1 billion valuation, moved their headquarters from the UK to Austin, and received FDA approval for their drug Aqneursa. To ensure the world knew about these monumental achievements and their promising future in 2025 and beyond, IntraBio tapped Hahn for Media Relations. Hahn secured coverage in both US and international outlets, highlighting IntraBio’s groundbreaking clinical operations, impact on patients, world-renowned staff, and innovative business model that’s disrupting the BioPharma industry.